Iterum Therapeutics plc — Investor Relations & Filings

Iterum Therapeutics plc is a pharmaceutical company focused on developing and commercializing differentiated anti-infectives to combat multi-drug resistant (MDR) pathogens. The company's lead product is sulopenem, a novel penem anti-infective compound developed in both oral and intravenous (IV) formulations. The oral formulation, ORLYNVAH™, has received U.S. FDA approval for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women caused by designated susceptible microorganisms. ORLYNVAH™ is the first oral penem antibiotic approved in the United States, addressing the need for new treatment options against the growing threat of antibiotic-resistant bacteria.